Skip to main content

Table 2 Effects of pemafibrate on atherogenic apolipoproteinB-containing lipoproteins in a phase II dose-ranging study

From: Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia

Parameter Placebo, (n = 35) Pemafibrate (K-877) mg/day Fenofibrate mg/day
100 (n = 36)
0.05 (n = 34) 0.1 (n = 37) 0.2 (n = 36) 0.4 (n = 36)
Total C 0.1 ± 9.8 −2.7 ± 11.4 −6.5 ± 11.9** −7.0 ± 11.3*** −5.3 ± 12.9* −6.0 ± 11.8**
Non-HDL-C 0.7 ± 12.8 −5.8 ± 12.4* −11.8 ± 14.0***††† −12.2 ± 13.8***††† −10.5 ± 14.2***††† −10.1 ± 14.2***††
VLDL-Ca 13.3 ± 38.9 −24.3 ± 24.0***††† −37.3 ± 26.7***††† −43.8 ± 24.0***††† −48.4 ± 27.5***††† −25.8 ± 29.7***†††
LDL-Ca −6.3 ± 16.2* 8.9 ± 21.3* 8.3 ± 29.4 5.0 ± 28.0 7.4 ± 26.5 5.3 ± 23.4
Remnant C 38.7 ± 75.7** −32.3 ± 33.8***††† −42.8 ± 29.4***††† −48.3 ± 28.1***††† −50.1 ± 31.8***††† −31.8 ± 35.0***†††
ApoB −2.0 ± 9.9 −1.4 ± 13.6 −8.9 ± 13.6*** −7.8 ± 15.0** −8.1 ± 11.6*** −5.7 ± 14.4*
ApoB48 54.6 ± 171.1 −28.4 ± 43.1***††† −43.1 ± 47.1***††† −55.9 ± 25.6***††† −51.2 ± 29.3***††† −37.9 ± 42.9***†††
ApoCIII 7.9 ± 27.4 −22.2 ± 14.4***††† −29.0 ± 18.9***††† −34.6 ± 17.7***††† −33.4 ± 19.2***††† −27.2 ± 18.9***†††
  1. Data are given as mean ± standard deviation (SD) for the percent change from baseline to week 12
  2. Apo apolipoprotein, C cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, VLDL very low-density lipoprotein
  3. Significantly different from baseline (week 0) * p < 0.05, ** p < 0.01, *** p < 0.001
  4. Significantly different from placebo p < 0.05, †† p < 0.01, ††† p < 0.001
  5. Figures in italics: significantly different from fenofibrate p < 0.01
  6. aMeasured by ultracentrifugation